Intellectual Property Management

Patents are not just legal shields, they’re powerful business assets. The way you license them can define whether your invention remains locked in a drawer or becomes a global phenomenon. Effective Patent Licensing Strategies include: 📌Exclusive Licensing – Giving one licensee full rights, often in exchange for higher royalties. 📌Non-Exclusive Licensing – Allowing multiple licensees, maximizing reach and volume. 📌Cross-Licensing – Two or more companies exchange patent rights, reducing litigation risk and fostering innovation. 📌Field-of-Use Licensing – Granting rights limited to specific industries or applications. 📌Sublicensing – Allowing the licensee to grant rights further, useful for scaling. 📌Case in Point: IBM’s Patent Licensing Strategy IBM is a textbook example. In the 1990s, IBM shifted focus from just making hardware to actively monetizing its vast patent portfolio. By licensing patents across industries, semiconductors, software, and IT, IBM generated over $1 billion annually in licensing revenue. 📌This strategy not only diversified revenue streams but also positioned IBM as a powerhouse of innovation while avoiding unnecessary litigation. A well-structured licensing strategy can transform patents into sustainable revenue, open new markets, and build strategic partnerships. #PatentStrategy #Innovation #Licensing #IPR #TechnologyBusiness #Patents

Strategic Life Cycle Management using combination therapies to extend patent life, improve efficacy, and combat competition. The focus is on Lotrel (a combination of Lotensin [benazepril] by Novartis and Norvasc [amlodipine] by Pfizer), both indicated for hypertension. Lotensin (an ACE inhibitor) had a patent expiration in 2003, while Norvasc (a calcium channel blocker) expired in 2007. By combining these two drugs, the complementary mechanisms provide added efficacy and safety, crucial for maintaining competitive positioning in the hypertension market. Value Added: 1. Enhanced Efficacy & Safety: Synergistic action from combining two distinct mechanisms of action (ACE inhibitor + Calcium Channel Blocker). 2. Extended Patent Protection: The combination patent adds 14 years, protecting the product from generic competition. 3. Prolonged Market Exclusivity: By utilizing Norvasc’s patent, the combination extends protection by 4 years post-Lotensin expiration. Life Cycle Management (LCM) is typically employed at critical points in a drug's life cycle, especially when it faces the following challenges: 1. Loss of Exclusivity (LOE): When a drug's patent is about to expire, generic competitors can enter the market. To delay this and maintain revenue streams, companies use LCM strategies like launching combination therapies, reformulations, or new indications. 2. Losing Market Share: If a drug starts losing market share due to increased competition or newer, more effective treatments, LCM can help revitalize the product. Companies may combine the drug with others to improve efficacy or safety, as seen with Lotrel (benazepril + amlodipine) or introduce patient-friendly formulations like extended-release versions. Patent Extensions: By launching combination therapies or reformulations, companies extend the patent life (e.g., the Lotrel combination provided 14 extra years).

A few people asked what it actually looks like to file patent applications the smart way. Here’s the framework I give startup teams who want to protect innovation without wasting capital: 1. Don’t file just because you “can.” Too many patent applications get filed on features that aren’t core to the product, the market, or the long-term strategy. Just because it’s technically new doesn’t mean it’s worth protecting. 2. Tie every filing to a business objective. What are you trying to accomplish? Protect revenue? Block a competitor? Support a valuation narrative? There needs to be a clear business case for every dollar spent on IP. 3. Prioritize enforceability over imagination. Broad, abstract patents might sound exciting, but they often fail when tested. Focus on what you can realistically enforce. If your claim can’t stand up in court or deter a competitor, it’s not helping you. 4. Treat foreign filings like investments — not checkboxes. Filing internationally gets expensive fast. File where you have customers, competitors, or partners. Not where “you might want protection someday.” 5. Reassess regularly. As your product evolves, your patent strategy should too. What mattered at seed stage may not matter at Series B. Trim the fat. Redirect capital where it matters. The bottom line: a strong patent strategy isn’t about quantity — it’s about alignment. The best portfolios are lean, targeted, and tied directly to how the company competes and grows. If you’re not sure whether your IP is doing that, it’s worth a second look.

Patent portfolios worth tens of millions in R&D investment are underutilized as "fire extinguishers" rather than active business assets, with companies missing opportunities for non-dilutive capital generation through outright sales, licensing programs, auctions, or revenue-sharing partnerships. Strategic monetization requires careful portfolio preparation including evidence of use documentation, logical patent bundling by technology area, and cross-functional alignment between IP counsel, R&D, and business units to maximize commercial appeal. The approach emphasizes creating competitive markets by targeting direct competitors, supply chain partners, patent aggregators, and investment funds, with successful programs treating patents as marketable assets comparable to brands or real estate rather than dormant legal artifacts awaiting litigation.

You can get multiple patents on the same product. That way you protect the product from multiple angles. Some companies overlook this advantage. A company builds a great product, files a single patent application, and moves on. Meanwhile the product evolves, competitors enter the market, and the original claims stop matching what actually matters. The better approach is to think in layers. Start with different types of protection: • Utility patents to cover how the product works • Design patents to cover how the product looks • Method claims to cover how the product is used or manufactured Each one targets a different type of competitor behavior. Even within utility patents, you are not limited to a single set of claims. You can pursue multiple device claims directed to different features or different combinations of features within the same product. That allows you to protect the core concept, as well as specific implementations that may become commercially important. But these are not all filed at the same time. They are layered by filing continuation applications to keep the family alive. In many cases, I prefer to start with a utility application focused on device claims. That usually provides the strongest and most direct protection against competitors making and selling the product. Method claims can be added later, either in the same application or through a continuation. Design patents can also be added once the commercial embodiment is finalized and worth protecting from a visual standpoint. Keeping a continuation pending allows you to adjust your claims over time. As the product changes, or as you learn more about competitors, you can draft new claims that better align with what is actually happening in the market. This is where a lot of value is created. Your first application is based on version 1 of the product. But by the time it issues, you may be on version 3. If you kept the family open, you can pursue claims directed to: • New features added after launch • Competitor design-arounds • Commercial embodiments that were not the focus on day one Without that flexibility, you could be stuck with claims that describe a product you no longer sell. The companies that build strong portfolios treat patents like a living asset.

The $2.23 billion bet on small molecule drugs is failing, not in the lab, but in the patent office. The structural weakness is clear: a mere five years of NCE exclusivity compared to 12 for biologics. Innovators relying solely on a core Composition of Matter (CoM) patent are accelerating their own generic cliff. This traditional, molecule-centric approach is now commercially obsolete. The pressure to recoup soaring R&D costs demands immediate action. Maximum ROI demands a radical shift to a "lifecycle-centric" IP strategy—a sophisticated Patent Fortress. Securing foundational CoM claims remains critical, ideally using a provisional filing to establish the earliest possible priority date and gain a 12-month development window. But maximizing market longevity requires continuous IP generation, integrating patent filing into every stage of R&D. The goal is to aggressively compensate for the statutory exclusivity deficit and ensure the effective market term approaches the 14-year maximum set by Patent Term Extension (PTE) rules. The robust defense perimeter consists of meticulously crafted secondary patents designed to survive Paragraph IV challenges and create regulatory barriers. Polymorph patents are the high-stakes layer; they claim specific crystalline forms, blocking generic formulation workarounds and triggering costly, 30-month litigation stays via Orange Book listing. This technical rigor translates directly into retained revenue. Beyond polymorphs, advanced Formulation Patents protect specific drug delivery systems and excipient ratios, provided they demonstrate an "unexpected benefit" that enhances bioavailability or stability. Furthermore, strategic Method of Use claims for new dosing regimens or patient subsets can secure an additional three years of New Clinical Investigation Exclusivity. Every secondary claim, every year of delay against generic entry, is a massive win. This isn't just legal strategy; it's sophisticated regulatory engineering essential for commercial success and shareholder value. #Drugs #Patents #Generics https://lnkd.in/eWSCAfBh

𝗦𝗼𝗳𝘁𝘄𝗮𝗿𝗲 𝗽𝗮𝘁𝗲𝗻𝘁𝘀 𝗮𝗿𝗲 𝗮 𝗱𝗲𝗳𝗲𝗻𝘀𝗶𝘃𝗲 𝗻𝗲𝗰𝗲𝘀𝘀𝗶𝘁𝘆 𝗮𝘁 𝗯𝗲𝘀𝘁. 𝗥𝗶𝗴𝗵𝘁? Here's my contrarian view: Strategic patent protection for software isn't just defensive—it's a competitive advantage that differentiates growing companies in tangible, valuable ways. For nearly 30 years, I've watched software companies leverage patents to raise investment, deter competitors, maximize acquisition value, and create cross-licensing leverage. Done strategically, patents become assets that actively drive business outcomes. Here's what strategic patent protection actually delivers: • 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗰𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝗰𝗲. Sophisticated investors evaluate whether you're building defensible technology. Patents signal protectable intellectual property, not just code anyone can replicate.    • 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝘃𝗮𝗹𝘂𝗲. Acquirers pay premiums for strong IP positions. A well-constructed patent portfolio can meaningfully impact valuation in exit discussions.    • 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗱𝗲𝘁𝗲𝗿𝗿𝗲𝗻𝗰𝗲. Patents create space for your innovation to gain market traction before competitors simply copy your approach.    • 𝗖𝗿𝗼𝘀𝘀-𝗹𝗶𝗰𝗲𝗻𝘀𝗶𝗻𝗴 𝗹𝗲𝘃𝗲𝗿𝗮𝗴𝗲. If approached with patent claims later, having your own portfolio creates negotiating options instead of one-sided licensing demands. And here's where FTO comes into play: strategic patent value is diminished if you're infringing others' patents. FTO and patent prosecution work together to create defensible competitive advantage. Consider two hypothetical AI startups with similar technology: • 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗔 views patents as unnecessary expenses. When raising Series B, investors ask about IP protection. The founders have no answers. When acquisition interest emerges, they have nothing proprietary to differentiate their technology. Their valuation reflects commodity technology. • 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗕 invested in targeted patent protection on core algorithms and conducted FTO analysis early. During fundraising, they demonstrate protectable innovation. During acquisition discussions, they present a patent portfolio covering key differentiators. Their valuation reflects strategic assets, not just revenue multiples. Same market. Similar products. Dramatically different strategic positioning. The goal isn't to patent everything you build. The goal is to identify your core innovations, protect them strategically, and ensure you have freedom to operate, creating a complete IP position that serves your business strategy. 𝗥𝗲𝗮𝗱𝘆 𝘁𝗼 𝘁𝘂𝗿𝗻 𝗜𝗣 𝘂𝗻𝗰𝗲𝗿𝘁𝗮𝗶𝗻𝘁𝘆 𝗶𝗻𝘁𝗼 𝗜𝗣 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲? 𝗟𝗲𝘁'𝘀 𝗱𝗶𝘀𝗰𝘂𝘀𝘀 𝘆𝗼𝘂𝗿 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗜𝗣 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻. #patents #ip

I have been getting a lot of calls lately. The question is always some version of: "How do I make money from my patents?" Here is what I tell every caller. First, know who is buying. The active buyers right now are licensing companies, PE-backed IP funds, and strategic acquirers building defensive portfolios. Each has different expectations for what they will pay and why. Second, know what they want. Broad claims, clear evidence of use in the market, and remaining life on the term. Narrow claims with 3 years left are not attracting serious offers. Third, do not spend money until you have done the basics. Before you hire a broker or licensing firm: Map your claims to products actually in the market. Identify who is using your technology and how. Assess claim strength against prior art. Get a realistic valuation from comparable transactions. Too many patent holders skip this work, hire an expensive intermediary, and wonder why nothing sells. The companies that succeed at monetization do their homework first. They build relationships with buyers over time. They present clean, well-documented portfolios with clear evidence of use. Patent monetization is real. But it is a strategy, not a lottery ticket. Thinking about monetizing your portfolio? Start with the research.

How Motorola built a $100M+ patent portfolio. Most companies patent their inventions. Smart companies patent around customer outcomes. Motorola used outcome-driven research in the fuel cell technology space to develop and receive nearly two dozen strategic patents, each addressing an important customer outcome. Their advantage: - Identified customer outcomes before competitors recognized them - Patented solutions to those outcomes early in the development cycle - Created licensing revenue streams worth $100M+ - Blocked competitor advances in the market The key insight: When you know where customer value will migrate, you can patent the pathway before competitors even see the destination. This transforms R&D from a cost center into a profit engine: - Generate licensing revenue from IP portfolios - Create barriers to competitor entry - Establish market leadership positions - Build sustainable competitive advantages The lesson: Don't just solve customer problems—own the intellectual property for solving the most valuable problems. Build a patent fence. How could Outcome-Driven insights guide your patent strategy?

🚀 Strategic IP Leaders: Patent Value Is a System, Not a Silo 🌍 Patents are powerful — but alone, they don’t create value. True IP value emerges when legal strength, technical readiness, market reality, and execution capability move together, supported by the right complementary assets. 📈🧠 Here’s a fast, executive-level scan of the essentials 👇 💰 Income-first mindset Expected cash flows matter more than theoretical value. DCF, probabilities, time and risk are not finance jargon — they are reality. ⏳📉 ⚖️ Layered risk thinking Legal, technical, and market risks must be assessed separately. Double-counting risk is one of the fastest ways to destroy valuation credibility. ⚙️📊 🧱 Legal strength as infrastructure Patent status, ownership clarity, patentability, invalidity exposure, Freedom-to-Operate, detectability and enforceability are structural pillars — not administrative checks. 🛡️ 🔬 Technical realism over optimism Development stage, probability of success, delays, and failure paths directly reshape value. Time-to-market is a valuation variable, not a footnote. ⏱️ 📊 Business-plan discipline Every valuation rests on assumptions. Question where the numbers come from, who benefits from them, and whether they survive independent scrutiny. 🔍 🧩 Complementary assets unlock value Know-how, capital, manufacturing, sales, regulatory approvals and processes are what convert exclusion rights into revenue. No complements, no cash flow. 🏭🤝 🌐 2026 and beyond — strategic follow-up for global IP leaders 🤖 AI everywhere AI-driven R&D and patent analytics accelerate innovation — and invalidity challenges. Faster cycles demand faster valuation updates. 🌍 Geopolitical fragmentation Selective filing, jurisdiction-by-jurisdiction ROI, and enforcement realism are now core portfolio decisions. ⏩ Shorter product lifecycles Scenario-based valuation beats static models. Protect the core, stay agile at the edges. 🔗 Standards & ecosystems Interoperability increases FTO complexity but also licensing opportunities. Standards strategy = IP strategy. 🕵️ Detectability becomes decisive IoT, software and data-driven enforcement tools will separate enforceable patents from theoretical ones. 🌱 ESG & climate-driven IP Green technologies bring new value streams — and new regulatory and patentability constraints. Integrate ESG into valuation logic early. ✨ Final thought If patents are still treated as standalone assets in your organization, value is being left on the table. I’m happy to exchange perspectives with IP strategy leaders navigating valuation, risk and execution in a fragmented global landscape. What’s the toughest challenge in your IP valuation today? 💬 #IPStrategy #PatentValuation #FTO #TechRisk #IPManagement #2026AndBeyond